Table 1 Details of prospective trials included
Relevant publication | N a | Age: Median (range) | Phase | Systemic Therapy |
|---|---|---|---|---|
Bekaii-Saab et al. 2011 [12] | 28 | 56 (26–79) | II, Non-randomised | Selumetinib |
Goldstein et al. 2011 [13] | 50 | 59 (39–78) | II, Non-randomised | Gemcitabine/Cisplatin |
Jensen et al. 2012 [14] | 46 | 66 (37–80) | II, Non-randomised | Gemcitabine/Oxaliplatin/Panitumumab/Capecitabine |
Lassen et al. 2011 [15] | 41 | 61 (35–75) | II, Non-randomised | Gemcitabine/Oxaliplatin/Capecitabine |
Malka et al. 2014 (BINGO) [16] | 150 | 62 (35–75) | II, Randomised | Gemcitabine/Oxaliplatin ± Cetuximab |
Moehler et al. 2014 (AIO) [17] | 102 | 64 (36–84) | II, Randomised | Gemcitabine ± Sorafenib |
Okusaka et al. 2010 (BT22) [18] | 83 | 66 (43–80) | II, Randomised | Gemcitabine ± Cisplatin |
Peck et al. 2012 [19] | 9 | 61 (31–83) | II, Non-randomised | Lapatinib |
Rao et al. 2005 [20] | 54 | 57 (36–76) | III, Randomised | 5-Fluorouracil/Etoposide/Leucovorin versus Epirubicin/Cisplatin/5-Fluorouracil |
Riechelmann et al. 2007 [21] | 75 | 61 (37–84) | II, Non-randomised | Gemcitabine/Capecitabine |
Ferraro et al. 2016 (TACTIC) [22] | 48 | 64 (40–82) | II, Non-randomised | Gemcitabine/Cisplatin/Panitumumab |
Valle et al. 2010 (ABC-02) [2] | 410 | 63 (23–85) | III, Randomised | Gemcitabine ± Cisplatin |
Wagner et al. 2009 [23] | 72 | 62 (36–80) | II, Non-randomised | Gemcitabine/Oxaliplatin/5-Fluorouracil |